Otros idiomas Apogee Therapeutics, Inc.

Acciones

APGE

US03770N1019

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
50,31 ^USD	-6,40 %		-5,47 %	+80,06 %

15/05	Apogee anuncia la dosificación del primer paciente en el ensayo de dermatitis atópica de fase 2 de APG777, un novedoso anticuerpo anti-Il-13 subcutáneo de vida media prolongada para el tratamiento de la dermatitis atópica y otras enfermedades inflamatorias	CI
13/05	Se amplía la pérdida neta de Apogee Therapeutics en el 1T	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	15/05
Apogee Therapeutics' Q1 Net Loss Widens	13/05
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results	13/05
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference	06/05
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases	25/03
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases	25/03
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index	18/03
Apogee Closes $483 million Upsized Stock Offering	12/03
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million	12/03
Apogee Therapeutics Prices Upsized $420 Million Share Offering	08/03
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering	08/03
Sector Update: Health Care Stocks Advance Wednesday Afternoon	06/03
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target	06/03
Apogee Therapeutics Unveils $350 Million Share Offering	05/03
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering	05/03
Sector Update: Health Care Stocks Retreating Late Afternoon	05/03
Sector Update: Health Care Stocks Lower Tuesday Afternoon	05/03
Top Midday Gainers	05/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Apogee Therapeutics, Inc.

Acciones

APGE

US03770N1019

Otros idiomas

Filtros